Shares of Medicure Inc. (CVE:MPH – Get Free Report) passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of C$1.44 and traded as low as C$1.38. Medicure shares last traded at C$2.59, with a volume of 3,114 shares changing hands.
Medicure Stock Performance
The company has a debt-to-equity ratio of 6.02, a quick ratio of 1.28 and a current ratio of 0.97. The company has a market cap of C$27.03 million, a PE ratio of -3.60 and a beta of 0.93. The business’s 50-day moving average is C$1.44 and its 200 day moving average is C$1.24.
About Medicure
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
See Also
- Five stocks we like better than Medicure
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
